Skip to main content
. 2021 Dec 31;12(6):2859–2868. doi: 10.1016/j.apsb.2021.12.017

Figure 5.

Figure 5

PROTAC A7 efficiently degrades tumoral NAMPT in vivo. (A) The pharmacokinetic parameters of A7. C57BL/6 mice were administrated with single dose of PROTAC A7 (50 mg/kg, i.p.), followed by the collection of plasma. (B) The concentrations of A7 in plasma at the indicated time points. Mice were treated as in (A). (C) The intratumoral concentration of PROTAC A7. CT26 tumor-bearing mice were treated with PROTAC A7 (16 or 50 mg/kg) for 7 consecutive days (n = 3). (D) Immunoblotting analysis for NAMPT in CT26 tumor tissue. Mice were treated as in (C).